Skip to content

Eli Lilly and Company Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Eli Lilly and Company · E.LLY.NYSE · United States
Use symbol E.LLY.NYSE in our API & Excel add-in to retrieve this data ↓
1,373.70
(+0.07%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 35.93%

Eli Lilly and Company Forecast

Eli Lilly and Company short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 35.9% a year, a typical one-standard-deviation range is 1,304–1,443 over a week, 1,231–1,516 over a month and 880.07–1,867 over a year. (Signals as of 1 Nov 2026.)

Eli Lilly and Company Price Chart

MacroFinance.ai

Eli Lilly and Company Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Eli Lilly and Company
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Eli Lilly and Company
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Eli Lilly and Company
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Eli Lilly and Company
P/E
44.50x
Mid-range vs own history
QoQ +5.9%
YoY −14.0%
now 44.498833.62 low52.74 high
ⓘP/E As of 22 Nov 2026.See Eli Lilly and Company returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Eli Lilly and Company
P/S
14.19x
Mid-range vs own history
QoQ +0.8%
YoY −11.4%
now 14.194311.76 low16.34 high
ⓘP/S As of 22 Nov 2026.See Eli Lilly and Company returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Eli Lilly and Company
P/B
30.48x
Cheap vs own history
QoQ −8.0%
YoY −23.9%
now 30.475127.24 low40.81 high
ⓘP/B As of 22 Nov 2026.See Eli Lilly and Company returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Eli Lilly and Company
EV/EBITDA
28.42x
Cheap vs own history
QoQ +5.4%
YoY −22.4%
now 28.42123.48 low37.32 high
ⓘEV/EBITDA As of 22 Nov 2026.See Eli Lilly and Company returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Eli Lilly and Company
EV/Sales
14.71x
Mid-range vs own history
QoQ +0.3%
YoY −11.3%
now 14.710312.29 low16.89 high
ⓘEV/Sales As of 22 Nov 2026.See Eli Lilly and Company returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Eli Lilly and Company
FCF Yield
1.6%
Mid-range vs own history
QoQ −10.4%
YoY +69.1%
now 1.6020.93 low2.01 high
ⓘFCF Yield As of 22 Nov 2026.See Eli Lilly and Company returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Eli Lilly and Company
Earnings Yield
2.2%
Mid-range vs own history
QoQ −5.6%
YoY +16.3%
now 2.24731.9 low2.97 high
ⓘEarnings Yield As of 22 Nov 2026.See Eli Lilly and Company returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Eli Lilly and Company
Dividend Yield
0.5%
Weak vs own history
QoQ −5.5%
YoY −10.9%
now 0.48730.46 low0.68 high
ⓘDividend Yield As of 22 Nov 2026.See Eli Lilly and Company returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Eli Lilly and Company
Market Cap
$1.23T
Highest in 5 years
QoQ +9.4%
YoY +28.9%
now 1227263.58788,661 low1,289,623 high
ⓘMarket Cap As of 22 Nov 2026.See Eli Lilly and Company returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Eli Lilly and Company
Net Debt
$44.6B
High vs own history
QoQ −2.9%
YoY +36.9%
now 4461832,593 low45,958 high
ⓘNet Debt As of 22 Nov 2026.See Eli Lilly and Company returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Eli Lilly and Company
Net Debt / EBITDA
1.00x
Low vs own history
QoQ −6.1%
YoY −17.7%
now 0.9971 low1.21 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Eli Lilly and Company returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Eli Lilly and Company
Current Ratio
1.39x
Mid-range vs own history
QoQ +2.5%
YoY −10.2%
now 1.38871.35 low1.58 high
ⓘCurrent Ratio As of 22 Nov 2026.See Eli Lilly and Company returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Eli Lilly and Company
Quick Ratio
1.00x
Mid-range vs own history
QoQ −0.1%
YoY −19.4%
now 1.00161 low1.24 high
ⓘQuick Ratio As of 22 Nov 2026.See Eli Lilly and Company returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Eli Lilly and Company
Interest Coverage
36.14x
Strong vs own history
QoQ −14.1%
YoY +29.7%
now 36.144127.87 low42.06 high
ⓘInterest Coverage As of 22 Nov 2026.See Eli Lilly and Company returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Eli Lilly and Company
Debt / Equity
1.23x
Low vs own history
QoQ −24.2%
YoY −31.2%
now 1.22921.23 low1.79 high
ⓘDebt / Equity As of 22 Nov 2026.See Eli Lilly and Company returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Eli Lilly and Company
Piotroski F-Score
8
Mid-range vs own history
QoQ −11.1%
YoY 0.0%
now 88 low9 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Eli Lilly and Company returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Eli Lilly and Company
Altman Z-Score
8.87
Mid-range vs own history
QoQ +8.4%
YoY +10.8%
now 8.87067.49 low9.82 high
ⓘAltman Z-Score As of 22 Nov 2026.See Eli Lilly and Company returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Eli Lilly and Company, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Eli Lilly and Company fundamentals: income statement, balance sheet & cash flow

Eli Lilly and Company reported revenue of $65.18bn and net income of $20.64bn in FY2025, the year ended 31 December 2025 — revenue up 44.7% and net income up 94.9% on the prior year. Free cash flow was $8.97bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$65.18bn
+44.7%
Net income
$20.64bn
+94.9%
Gross margin
83.04%
Free cash flow
$8.97bn
+138.6%
Net debt
$35.24bn
Shares short (30 Oct 2026)
7.21m
2.66 days to cover
Eli Lilly and Company income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue65.1845.0434.1228.5428.32
Cost of revenue11.058.427.086.637.31
Gross profit54.1336.6327.0421.9121.01
Research & development13.3410.999.317.197.03
Selling, general & admin.11.098.596.94——
Operating income29.7017.0410.797.136.36
EBITDA31.6918.818.578.668.04
Interest expense0.800.780.490.330.34
Pre-tax income25.7312.686.556.816.16
Income tax5.092.091.310.560.57
Net income20.6410.595.246.245.58

Download Eli Lilly and Company fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.LLY.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Eli Lilly and Company

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Eli Lilly and Company Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Eli Lilly and Company; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Eli Lilly and Company’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Eli Lilly and Company behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Eli Lilly and Company (United States)

Eli Lilly and Company is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Eli Lilly and Company

Frequently asked questions

What is Eli Lilly and Company?
Eli Lilly and Company is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Eli Lilly and Company price?
The latest close is 1,374 (1 Nov 2026), +0.07% on the day. The price at the top of the page refreshes during the trading day.
Is Eli Lilly and Company in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Eli Lilly and Company?
20-day realised volatility is 35.9% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 10.4% over a month and 5.1% over a week.
What factors affect Eli Lilly and Company?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Eli Lilly and Company, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Eli Lilly and Company?
58 backtested tactical asset allocation strategies trade Eli Lilly and Company through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Eli Lilly and Company returns analysed?
The Statistical Distribution of Returns section shows the distribution of Eli Lilly and Company daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Eli Lilly and Company historical data?
In the Free historical data section of this page: the last 10 years of Eli Lilly and Company daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Eli Lilly and Company historical data (last 10 years)

Browse or instantly download the last 10 years of Eli Lilly and Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.LLY.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-201347.11
2026-11-191351.12
2026-11-181382.75
2026-11-171415.55
2026-11-161431.67
2026-11-131443.5
2026-11-121425.55
2026-11-111435.55
2026-11-101430.55
2026-11-091410.24
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.